Document Detail


Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension.
MedLine Citation:
PMID:  18091737     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although the therapeutic response to angiotensin II receptor blockers (ARBs) is assumed impaired in patients with low-renin hypertension, data are scarce about the association between levels of plasma renin activity (PRA) before treatment and response of ambulatory blood pressure (ABP) to ARBs in essential hypertension.
METHODS: We prospectively studied 11 untreated Japanese patients with essential hypertension (3 women and 8 men, mean age: 50 +/- 9 (mean +/- SD) years). After a 4-week drug-free period, telmisartan 20-40 mg was administered orally once daily for 8 weeks. PRA levels were measured before treatment. The first ABP measurement was performed at the end of the drug-free period and the second measurement at the end of the treatment period with telmisartan.
RESULTS: Telmisartan significantly decreased the 24-h ABP by 12 +/- 11 mm Hg systolic (P < 0.01) and 9 +/- 8 mm Hg diastolic (P < 0.01). Reductions in the 24-h systolic and diastolic ABPs were significantly greater in five patients with higher renin levels (> or =0.65 ng/ml/h) than in six patients with lower renin levels (<0.65 ng/ml/h) by 18 mm Hg systolic (P < 0.001) and 11 mm Hg diastolic (P < 0.05). Changes in the 24-h systolic and diastolic ABPs significantly correlated with log PRA before treatment.
CONCLUSIONS: The ABP lowering effects of telmisartan were dependent on PRA levels before treatment in patients with essential hypertension. Measurement of PRA levels before treatment is thought to be useful for prediction of the ABP lowering effects of telmisartan.
Authors:
Junichi Minami; Toshihiko Ishimitsu; Hiroaki Matsuoka
Related Documents :
7020487 - Propranolol alters renin release during nitroprusside-induced hypotension and prevents ...
8901817 - Pressure-dependent renin release during chronic blockade of nitric oxide synthase.
6219527 - Persistence of unilateral secretion and contralateral renin suppression after successfu...
8319997 - Comparative effects of three different potent renin inhibitors in primates.
17539797 - Late intraocular pressure rise following intravitreal triamcinolone injection.
15510927 - Non-invasive determination of left ventricular relaxation time constant by transthoraci...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  American journal of hypertension     Volume:  21     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-19     Completed Date:  2008-03-13     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  10-3     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  therapeutic use*
Asian Continental Ancestry Group
Benzimidazoles / administration & dosage,  therapeutic use*
Benzoates / administration & dosage,  therapeutic use*
Biological Markers / blood
Blood Pressure / drug effects*
Blood Pressure Monitoring, Ambulatory
Drug Administration Schedule
Female
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Japan
Male
Middle Aged
Patient Selection
Prospective Studies
Renin / blood*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Biological Markers; EC 3.4.23.15/Renin; U5SYW473RQ/telmisartan
Comments/Corrections
Comment In:
Am J Hypertens. 2008 Jan;21(1):5-6   [PMID:  18091734 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Deriving structure from evolution: metazoan segmentation.
Next Document:  Carryover effects after cessation of drug treatment: trophies or dreams?